Industry / United States
AstraZeneca Submits NDA For Brilinta In US
November 2009 | Industry Trend AnalysisMultinational drugmaker AstraZeneca has submitted a New Drug Application (NDA) to the US Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is Brilinta, pending approval from the FDA. The approval process also commenced with European regulators in October.
To read the full article, please choose one of the following options:
Subcribers please log in
